Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 5/2014

Open Access 01-05-2014 | Nephrology - Review

Lipid, blood pressure and kidney update 2013

Authors: Maciej Banach, Corina Serban, Wilbert S. Aronow, Jacek Rysz, Simona Dragan, Edgar V. Lerma, Mugurel Apetrii, Adrian Covic

Published in: International Urology and Nephrology | Issue 5/2014

Login to get access

Abstract

The year 2013 proved to be very exciting as far as landmark trials and new guidelines in the field of lipid disorders, blood pressure and kidney diseases. Among these are the International Atherosclerosis Society Global Recommendations for the Management of Dyslipidemia, European Society of Cardiology (ESC)/European Society of Hypertension Guidelines for the Management of Arterial Hypertension, American Diabetes Association Clinical Practice Recommendations, the Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease (CKD) Patients, the American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, the Joint National Committee Expert Panel (JNC 8) Evidence-Based Guideline for the Management of High Blood Pressure in Adults, the American Society of Hypertension/International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Community, the American College of Physicians Clinical Practice Guideline on Screening, Monitoring, and Treatment of Stage 1–3 CKD and many important trials presented among others during the ESC Annual Congress in Amsterdam and the American Society of Nephrology Annual Meeting—Kidney Week in Atlanta, GA. The paper is an attempt to summarize the most important events and reports in the mentioned areas in the passing year.
Footnotes
1
First phase II study report on polynuclear iron(III)-oxyhydroxide phosphate binder (PA21) in hyperphosphatemic hemodialysis patients.
 
2
Prospective, phase III, multicenter, open-label, randomized clinical trial using ferric citrate in hyperphosphatemic hemodialysis patients.
 
Literature
1.
Banach M, Rysz J (2010) Current problems in hypertension and nephrology. Expert Opin Pharmacother 11(16):2575–2578PubMed
2.
Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D (2011) European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(1):3–46PubMed
3.
Tonelli M, Wanner C; for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members (2014) Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med. doi:10.​7326/​M13-2453
4.
KDIGO (2013) clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 3:259–305
5.
Stone NJ, Robinson J, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. doi:10.​1161/​01.​cir.​0000437738.​63853.​7a
6.
7.
8.
Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z (2012) How can we further improve the LDL-cholesterol target level achievement rate based on the Hungarian MULTI GAP 2011 study results and considering the new European dyslipidemia guidelines? Arch Med Sci 8(4):608–613PubMedPubMedCentral
9.
Mitka M (2013) Groups release new, updated guidelines to reduce heart disease risk factors. JAMA 310(24):2602–2604PubMed
10.
Rizzo M, Banach M, Montalto G, Mikhailidis DP (2012) Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci 8(4):598–600PubMedPubMedCentral
11.
Rizzo M, Nikolic D, Banach M, Montalto G (2013) Statin treatment in the elderly: how much do we know? Arch Med Sci 9(4):585–588PubMedPubMedCentral
12.
Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M et al (2012) Lipid-related markers and cardiovascular disease prediction. JAMA 307(23):2499–2506PubMed
13.
Lai HM, Aronow WS, Mercando AD, Kalen P, Desai HV, Gandhi K, Sharma M, Amin H, Lai TM (2012) The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. Arch Med Sci 8(1):53–56PubMedPubMedCentral
14.
Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z (2011) An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS Program. Arch Med Sci 2011(7):760–766
15.
Wiklund O, Pirazzi C, Romeo S (2013) Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep 15(9):397PubMedPubMedCentral
16.
Smith JD (2010) Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 30(2):151–155PubMedPubMedCentral
17.
Rothblat GH, Phillips MC (2010) High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21(3):229–238PubMedPubMedCentral
18.
Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A et al (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57(3):392–410PubMed
19.
Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51(4):314–324PubMed
20.
Banach M, Hering D, Narkiewicz K, Mysliwiec M, Rysz J, Malyszko J (2012) Lipids, blood pressure, kidney-what was new in 2012? Int J Pharmacol 8:659–678
21.
Oravec S, Dukat A, Gavornik P, Lovasova Z, Gruber K (2011) Atherogenic normolipidemia—a new phenomenon in the lipoprotein profile of clinically healthy subjects. Neuro Endocrinol Lett 32(3):317–321PubMed
22.
Kucera M, Oravec S, Hirnerova E, Huckova N, Celecova Z, Gaspar L, Banach M (2014) Effect of atorvastatin on low density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity—A pilot study. Angiology. doi:10.​1177/​0003319713507476​
23.
Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A et al (2011) “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 9(5):531–532PubMed
24.
Paraskevas KI, Koupidis S, Gentimi F, Tzovaras AA (2011) Statin discontinuation: counterbalancing the benefits with the potential risks. Arch Med Sci 7(6):1076–1077PubMedPubMedCentral
25.
26.
Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J (2013) The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol 45(6):1605–1612PubMedPubMedCentral
27.
Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmański R, Pawlicki L (2006) Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 48(4):143–147PubMed
28.
Bielecka-Dabrowa A, Mikhailidis DP, Rizzo M, von Haehling S, Rysz J, Banach M (2013) The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy—5-year follow-up. Lipids Health Dis 12(1):47PubMedPubMedCentral
29.
30.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735–742PubMed
31.
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM (2009) Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32(10):1924–1929PubMedPubMedCentral
32.
Shah RV, Goldfine AB (2012) Statins and risk of new-onset diabetes mellitus. Circulation 126(18):e282–e284PubMed
33.
Axsom K, Berger JS, Schwartzbard AZ (2013) Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep 15(2):299PubMed
34.
Banach M, Mikhailidis DP (2013) Statin therapy and new-onset diabetes: an attempt at recommendations. Exp Rev Endocrinol Metab 8(3):213–216
35.
Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A (2013) Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 19(27):4904–4912PubMed
36.
37.
Zaharan NL, Williams D, Bennett K (2013) Statins and risk of treated incident diabetes in a primary care population. Brit J Clin Pharmacol 75(4):1118–1124
38.
Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC (2013) Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an Asian country. PLoS One 8(8):e71817PubMedPubMedCentral
39.
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346:f2610PubMedPubMedCentral
40.
Izzo R, de Simone G, Trimarco V, Giudice R, De Marco M, Di Renzo G et al (2013) Primary prevention with statins and incident diabetes in hypertensive patients at high cardiovascular risk. Nutr Metab Cardiovasc Dis. doi:10.​1016/​j.​numecd.​2012.​11.​002
41.
42.
Katsiki N, Banach M (2012) Statins and the risk of diabetes: the debate. Arch Intern Med 172(11):895–896PubMed
43.
Athyros VG, Hatzitolios AI, Karagiannis A, Savopoulos C, Katsiki N, Tziomalos K, Papagianni A, Kakafika A, Gossios TD, Mikhailidis DP, IMPERATIVE Collaborative Group (2011) IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 7(6):984–992PubMedPubMedCentral
44.
Kostapanos MS, Milionis HJ, Elisaf MS (2010) Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 11(16):2635–2650PubMed
45.
Kalinowski L, Dobrucki IT, Malinski T (2002) Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol 53(4 Pt 1):585–595PubMed
46.
John S, Schneider MP, Delles C, Jacobi J, Schmieder RE (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149(3):473PubMed
47.
Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J (2009) Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 25(8):1995–2005PubMed
48.
Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J (2009) Time for new indications for statins? Med Sci Monit 15(12):MS1–5PubMed
49.
Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M et al (2001) Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154(1):87–96PubMed
50.
Aydin U, Ugurlucan M, Gungor F, Ziyade S, Inan B, Banach M et al (2009) Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology 60(3):370–377PubMed
51.
Tycinska AM, Janica J, Mroczko B, Musial WJ, Sawicki R, Sobkowicz B, Kaminski K, Lebkowska U, Szmitkowski M (2011) Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction. Arch Med Sci 7(6):955–962PubMedPubMedCentral
52.
Feldstein CA (2010) Statins in hypertension: are they a new class of antihypertensive agents? Am J Ther 17(3):255–262PubMed
53.
Katsiki N, Mikhailidis DP, Banach M (2011) Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 29(12):2493–2494PubMed
54.
Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, Lipid and Blood Pressure Meta-Analysis Collaboration Group et al (2013) The effects of statins on blood pressure in normotensive or hypertensive subjects—a meta-analysis of randomized controlled trials. Int J Cardiol 168(3):2816–2824PubMed
55.
Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M (2013) Metabolic syndrome and renal disease. Int J Cardiol 164(2):141–150PubMed
56.
Franczyk-Skora B, Gluba A, Banach M, Rozentryt P, Polonski L, Rysz J (2013) Acute coronary syndromes in patients with chronic kidney disease. Curr Vasc Pharmacol 11(5):758–767PubMed
57.
Stępien M, Stępien A, Wlazel RN, Paradowski M, Banach M, Rysz M, Rysz J (2013) Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Med Sci Monit 19:1063–1072PubMedPubMedCentral
58.
Franczyk-Skora B, Gluba A, Banach M, Rysz J (2013) Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Arch Med Sci 9(6):1019–1027PubMedPubMedCentral
59.
Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M (2009) Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 13(5):541–550PubMed
60.
Athyros VG, Katsiki N, Tziomalos K, Gossios TD, Theocharidou E, Gkaliagkousi E, Anagnostis P, Pagourelias ED, Karagiannis A, Mikhailidis DP, GREACE Study Collaborative Group (2013) Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 9(3):418–426PubMedPubMedCentral
61.
Gluba A, Rysz J, Banach M (2010) Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 11(16):2665–2674PubMed
62.
Nikolic D, Nikfar S, Salari P, Rizzo M, Ray KK, Pencina MJ, Lipid and Blood Pressure Meta-Analysis Collaboration Group et al (2013) Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin 29(5):435–451PubMed
63.
Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, Lipid and Blood Pressure Meta-Analysis Collaboration Group et al (2013) A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 168(6):5437–5447PubMed
64.
Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Lipid and Blood Pressure Meta-Analysis Collaboration Group et al (2013) Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 72:35–44PubMed
65.
66.
Banach M, Lipid, Blood Pressure Meta-Analysis Collaboration Group (2013) Statins in patients with chronic kidney disease—an attempt at recommendations. Curr Med Res Opin 29(11):1419–1422PubMed
67.
Shekhar Pandey A, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS (2011) Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: the EZE(STAT)2 trial. Arch Med Sci 7(5):767–775PubMedPubMedCentral
68.
Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F et al (2012) Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol 59(20):1778–1784PubMed
69.
Stein EA, Raal FJ (2013) Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation 127(24):2372–2374PubMed
70.
Luna Saavedra YG, Zhang J, Seidah NG (2013) PCSK9 prosegment chimera as novel inhibitors of LDLR degradation. PloS One 8(8):e72113PubMedPubMedCentral
71.
Poirier S, Mayer G (2013) The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 7:1135–1148PubMedPubMedCentral
72.
Banach M, Rizzo M, Obradovic M, Montalto G, Rysz J, Mikhailidis DP et al (2013) PCSK9 inhibition—a novel mechanism to treat lipid disorders? Curr Pharm Des 19(21):3869–3877PubMed
73.
Mayne J, Ooi TC, Raymond A, Cousins M, Bernier L, Dewpura T et al (2013) Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis 12:70PubMedPubMedCentral
74.
Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 8(5):e64145PubMedPubMedCentral
75.
Catapano AL, Papadopoulos N (2013) The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228(1):18–28PubMed
76.
Desai NR, Kohli P, Giugliano RP, O’Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS (2013) AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 128(9):962–969PubMed
77.
Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380(9858):1995–2006PubMed
78.
Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA (2012) Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308(23):2497–2506PubMed
79.
Aronow WS, Fleg JL, Pepine CJ et al (2011) ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 57:2037–2114PubMed
80.
Beckett NS, Peters R, Fletcher AE et al (2008) Treatment of hypertension in patients 80 years of age or older. N Eng J Med 358:1887–1898
81.
Aronow WS (2011) Hypertension guidelines. Hypertension 58:347–348PubMed
82.
Aronow WS, Banach M (2012) Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press 21:3–5PubMed
83.
Banach M, Michalska M, Kjeldsen SE et al (2011) What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother 12:1835–1844PubMed
84.
Aronow WS (2012) What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci 8:399–402PubMedPubMedCentral
85.
Banach M, Aronow WS (2011) Should we have any doubts about hypertension therapy in elderly patients. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn 2011(121):253–258
86.
Aronow WS (2014) Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly. Am J Therap. doi:10.​1097/​MJT.​Ob013e3182217894​
87.
88.
Banach M, Aronow WS (2012) Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens 26:641–643PubMed
89.
Barylski M, Malyszko J, Rysz J et al (2011) Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 7:1055–1066PubMedPubMedCentral
90.
Egan BM, Li J, Qanungo S, Wolfman TE (2013) Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation 128(1):29–41PubMed
91.
Rizzo M, Montalto G, Banach M (2012) The effects of statins on blood pressure: current knowledge and future perspectives. Arch Med Sci 8:1–3PubMedPubMedCentral
92.
Gharipour M, Kelishadi R, Khosravi A et al (2012) The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001–2007. Arch Med Sci 8:1009–1017PubMedPubMedCentral
93.
Malyszko J, Bachorzewska-Gajewska H, Malyszko J et al (2011) Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 7:658–664PubMedPubMedCentral
94.
Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, Banach M (2012) An update on biomarkers of heart failure in hypertensive patients. J Hypertens 30(9):1681–1689PubMed
95.
Mozdzan M, Wierzbowska-Drabik K, Kurpesa M et al (2013) Echocardiographic indices of left ventricular hypertrophy and diastolic function in hypertensive patients with preserved LVEF classified as dippers and non-dippers. Arch Med Sci 9:268–275PubMedPubMedCentral
96.
Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M (2011) The Rise and Fall of Hypertension: lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep 5(2):174–179PubMedPubMedCentral
97.
Dorobanţu M, Darabont R, Ghiorghe S, Arsenescu-Georgescu C, Macarie C, Mitu F, Lighezan D, Musetescu R, Pop C, Ardeleanu E, Craiu E (2014) T Latin Small Letter A With Caron Utu OF. Hypertension prevalence and control in Romania at a seven-year interval. Comparison of SEPHAR I and II surveys. J Hypertens 32(1):39–47PubMed
98.
Stępień M, Wlazeł RN, Paradowski M, Banach M, Rysz M, Misztal M, Rysz J (2012) Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients—pilot study. Arch Med Sci 8(3):431–436PubMedPubMedCentral
99.
Jaffe MG, Lee GA, Young JD et al (2013) Improved blood pressure control associated with a large-scale hypertension program. JAMA 310:699–705PubMed
100.
Liu L, An Y, Chen M et al (2013) Trends in the prevalence of hospitalization attributable to hypertensive diseases among United States adults aged 35 and older from 1980 to 2007. Am J Cardiol 112:694–699PubMed
101.
Juhola J, Magnussen CG, Berenson GS et al (2013) Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis. The International Childhood Cardiovascular Cohort Consortium. Circulation 128:217–224PubMed
102.
The SPS3 Study Group (2013) Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382:507–515
103.
Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M et al (2013) Stroke in hypertension optimal treatment (SHOT) trial: protocol and organization. J Hypertens 31(e-Suppl A):e255
104.
Malyszko J, Muntner P, Rysz J, Banach M (2013) Blood pressure levels and stroke—J-curve phenomenon? Curr Hypertens Rep 15(6):575–581
105.
Siebert J, Gutknecht P, Molisz A, Trzeciak B, Nyka W (2012) Hemodynamic findings in patients with brain stroke. Arch Med Sci 8(2):371–374PubMedPubMedCentral
106.
American Diabetes Association. Position statement. Standards of Medical Care in Diabetes-2013. Diabetes Care 2013; 36(Suppl 1):S11–S66
107.
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 3. Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Suppl 2:357–362 (2012)
108.
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 4. Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl 2:363–369 (2012)
109.
Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357PubMed
110.
Gowin E, Avonts D, Horst-Sikorska W, Dytfeld J, Michalak M (2012) Stimulating preventive procedures in primary care. Effect of PIUPOZ program on the delivery of preventive procedures. Arch Med Sci 8(4):704–710PubMedPubMedCentral
111.
Alagiakrishnan K, Banach M, Jones LG, Ahmed A, Aronow WS (2013) Medication management of chronic heart failure in older adults. Drugs Aging 30(10):765–782PubMed
112.
Rogowicz-Frontczak A, Araszkiewicz A, Pilacinski S, Zozulinska-Ziolkiewicz D, Wykretowicz A, Wierusz-Wysocka B (2012) Carotid intima-media thickness and arterial stiffness in type 1 diabetic patients with and without microangiopathy. Arch Med Sci 8:484–490PubMedPubMedCentral
113.
Chandy D, Aronow WS, Banach M (2013) Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 6:101–109PubMedPubMedCentral
114.
Banach M, Bromfield S, Howard G et al (2013) Optimal blood pressure levels in elderly persons in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. Presented at 2013 European Society of Cardiology (ESC) Meeting, Amsterdam, The Netherlands
115.
James PA, Oparil S, Carter BL et al (2013) 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. doi:10.​1001/​jama.​2013.​284427
116.
Mann JF, Schmieder RE, McQueen M, ONTARGET Investigators et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553PubMed
117.
Parving HH, Brenner BM, McMurray JJ, ALTITUDE Investigators et al (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213PubMed
118.
Fried LF, Emanuele N, Zhang JH, VA NEPHRON-D Investigators et al (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903PubMed
119.
Weber MA, Schiffrin EL, White WB et al (2014) Clinical practice guidelines for the management of hypertension in the community: a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertens (Greenwich) 16(1):14–26
120.
ASTRAL Investigators, Wheatley K, Ives N, Gray R et al (2009) Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361(20):1953–1962PubMed
121.
Bax L, Woittiez AJ, Kouwenberg HJ et al (2009) Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 150(12):840–848 (W150-1)PubMed
122.
Cooper CJ, Murphy TP, Cutlip DE, CORAL Investigators et al (2014) Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370(1):13–22PubMed
123.
Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281PubMed
124.
Esler MD, Krum H, Schlaich M, Symplicity HTN-2 Investigators et al (2012) Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 126(25):2976–2982PubMed
125.
126.
127.
Qaseem A, Hopkins RH, Sweet DE, Starkey M, Shekelle P (2013) Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the clinical guidelines committee of the American college of physicians. Ann Intern Med. doi:10.​7326/​0003-4819-159-12-201312170-00726
128.
129.
Delmez JA, Slatopolsky E et al (1992) Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19(4):303PubMed
130.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl S1
131.
Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382(9900):1268PubMed
132.
Locatelli F, Dimkovic N, Pontoriero G et al (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transpl 25:574–581
133.
Wüthrich RP, Chonchol M, Covic A et al (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280–289PubMedPubMedCentral
134.
Dwyer JP, Sika M, Schulman G et al (2013) Collaborative Study GroupDose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 61:759–766PubMed
135.
Asif A, Epstein M et al (2004) Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 44(1):12PubMed
136.
Garlid KD, Costa ADT, Quinlan CL, Pierre SV, Dos Santos P (2009) Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 46:858–866PubMedPubMedCentral
137.
Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, Kubacki T, Benzing T, Erdmann E, Burst V, Gassanov N (2012) Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation 126(3):296PubMed
138.
Deftereos S, Giannopoulos G, Tzalamouras V, Raisakis K et al (2013) Renoprotective effect of remote ischemic post-conditioning by intermittent balloon inflations in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 61(19):1949–1955 (Epub 2013 Mar 14)PubMed
139.
140.
Sterns RH, Rojas M, Bernstein P, Chennupati S (2010) Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21(5):733–735PubMed
141.
142.
143.
Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108(6):1830–1834PubMed
144.
Yao S (2012) FDA approves Omontys to treat anemia in adult patients on dialysis (press release). US FDA. Retrieved April 29, 2012
145.
Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM, Besarab A (2013) Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 368(4):307–319PubMed
146.
Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola PE, Zabaneh RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM, Fishbane S (2013) Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 368(4):320–332PubMed
147.
Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407PubMedPubMedCentral
148.
Hussain JA, Mooney A, Russon L et al (2013) Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Palliat Med 27(9):829–839PubMed
149.
Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347(7):488PubMed
150.
Hirsch HH, Vincenti F, Friman S et al (2013) Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cysclosporine: a prospective, randomized, multicenter study. Am J Transpl 13(1):136–145
151.
Acott PD, O’Regan PA, Lee HS, Crocke JF (2008) In vitro effect of cyclosporine A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 10:385–390PubMed
152.
Pereyra F, Rubin RH (2004) Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 17(4):357PubMed
153.
Kotton CN, Kumar D, Caliendo AM et al (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:333–360PubMed
Metadata
Title
Lipid, blood pressure and kidney update 2013
Authors
Maciej Banach
Corina Serban
Wilbert S. Aronow
Jacek Rysz
Simona Dragan
Edgar V. Lerma
Mugurel Apetrii
Adrian Covic
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0657-6

Other articles of this Issue 5/2014

International Urology and Nephrology 5/2014 Go to the issue

Urology - Original Paper

Renal transplantation through a modified non-muscle-cutting Pfannenstiel incision

Urology - Original Paper

Protective effect of doxycycline on germinal epithelial loss caused by a high-fat diet

Nephrology - Original Paper

Calcification of the thoracic aorta determined by three-dimensional computed tomography predicts cardiovascular complications in patients undergoing hemodialysis

Nephrology - Original Paper

Sexual dysfunction is more than twice as frequent in Danish female predialysis patients compared to age- and gender-matched healthy controls

Urology - Original Paper

Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population

Urology - Original Paper

The value of the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system as a predictor of biochemical recurrence after radical prostatectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits